t:slim X2™ Insulin Pump with Control-IQ™ Technology
Control-IQ™ technology is the latest remote software update for your Tandem t:slim X2 insulin pump.
Trying to keep your blood sugar in range can be stressful and time consuming. The Control-IQ advanced hybrid closed-loop technology on the t:slim X2 insulin pump can make it easier by predicting and helping to prevent lows AND highs.
Control-IQ uses Dexcom G7 continuous glucose monitoring (CGM) values to predict glucose levels 30 minutes ahead and automatically adjusts insulin to help increase time in range (3.9 – 10 mmol/L).|| Dexcom G7 is a real-time, integrated continuous glucose monitoring (CGM) system requiring ZERO fingerpricks for calibration or mealtime dosing.^
Funding has now been expanded for the t:slim X2 insulin pump for New Zealanders living with type 1 diabetes.* Click here to learn more and check eligibility criteria click.
For more information, please contact NZMS Diabetes on 0800 500 226 or at diabetes@nzms.co.nz
Don’t miss out on a free upgrade!
The Control-IQ™ software update is FREE** if you have an in-warranty Tandem t:slim X2 pump. Contact us for more information.
Key Features
Predictive Technology
Designed to help prevent highs or lows and to increase time in range (3.9 – 10 mmol/L)§, Control-IQ technology predicts glucose values 30 minutes ahead.
Automatic Insulin Adjustments
Control-IQ™ technology automatically adjusts insulin levels based on Dexcom G7 CGM readings.§
Correction Boluses
For added protection, Control-IQ technology can also deliver automatic correction boluses (up to one an hour) to help prevent hyperglycaemia.†
Activity Settings
Control-IQ technology includes optional settings for Sleep and Exercise that adjust range of treatment values for more targeted control.
How Control-IQ works
Control-IQ technology predicts glucose values 30 minutes ahead, based on Dexcom G7 CGM readings, and can decrease or stop basal insulin delivery to help prevent lows, or increase basal insulin delivery to help avoid highs.
Control-IQ Status Icon: Icons display on the pump screen to visually indicate when insulin delivery is increasing, decreasing, or stopped. Please refer to the table for a breakdown of status icons.
- Dexcom G7 CGM integration with the t:slim X2 pump:
- Dexcom G7 Continuous Glucose Monitor (CGM) is now funded for people living with type 1 diabetes.*
- Dexcom G7 CGM consists of a tiny sensor inserted just under your skin and transmits real-time glucose readings to your pump or to your compatible smartphone alerting you of upcoming highs and lows. Dexcom G7 requires ZERO fingerpricks for calibration or mealtime dosing.^
- Note: The t:simulator™ app lets you experience the touchscreen interface of the t:slim X2™ insulin pump and see a simulation of Control-IQ technology using your smart device.
Get started on Control-IQ
How to get started on the t:slim X2 insulin pump with Control-IQ Technology:
The Tandem t:slim X2 Insulin Pump with Control-IQ Technology and consumables are fully funded for eligible patients through PHARMAC.* To find out more about the PHARMAC Funding Criteria for insulin pumps, click here.
- Speak to a diabetes specialist team to discuss the eligibility criteria and determine if the Tandem t:slim X2™ insulin pump is suitable.
- The diabetes specialist team will need to apply for a Special Authority. Once approved, a funded prescription will be issued.
- Prescriptions can be processed by local pharmacies.
- Your diabetes specialist team will refer you to an NZMS sales representative to arrange your Tandem pump training. Alternatively, you can reach out to us at NZDiabetesFunding@dexcom.com to arrange it. Once you start on the Tandem t:slim X2 insulin pump you can upgrade to Control-IQ as soon as you complete the Control-IQ training module and the update form.
For more information on PHARMAC Funding please visit our information page.
Are you on the t:slim X2 insulin pump with Basal-IQ Technology and want to upgrade to Control-IQ Technology?
You can upgrade to Control-IQ as soon as you complete the Control-IQ training module and the update form.
Need help in this upgrade process or want more information about Control-IQ? Complete our contact form here to speak to a representative.
Frequently Asked Questions
For additional resources, please visit our resources page or contact NZMS Diabetes on 0800 500 226.
Step 1 – Compete the ‘Update to Control IQ’ form
Step 2 – NZMS will send you the Control IQ online training link. Complete the online training (approx. 30 mins).
Step 3 – NZMS will email your personal update code and instructions on how to update from your home computer.
For more information about Dexcom G7, please click here.
NZMS Diabetes provide 24/7 technical support on 0508 634 103 for your t:slim X2 Insulin Pump as well as Dexcom G7 CGM System.
Visit our Support page for more information.
References and Important Risk Information
Always read the label and use only as directed. Read the warnings available on nzmsdiabetes.co.nz/resources before purchasing. Consult your healthcare professional to see if this product is right for you.
The t:slim X2 insulin pump provides continuous delivery of insulin through a subcutaneously applied infusion set. The algorithm will adjust insulin delivery according to the predicted glucose when used with a compatible CGM.
Dexcom CGM is a continuous glucose monitoring system indicated for the management of (type 1, type 2, gestational) diabetes in people age 2 years and older where self-monitoring of blood glucose (SMBG) is indicated.
*Eligibility criteria apply. Visit pharmac.govt.nz to learn more.
|| As measured by CGM.
^If your glucose alerts and readings from the G7 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
**Dexcom G7 CGM is required to use the Tandem t:slim X2 insulin pump with Control-IQ Technology.
§Dexcom CGM sold separately. Transmitter can only be paired with one medical device (either a Dexcom receiver or t:slim X2 insulin pump) and one consumer device (phone or tablet) at the same time.
†If glucose values are predicted to be above 10,0 mmol/L, Control-IQ technology calculates a correction bolus using the Personal Profile settings and a target of 6,1 mmol/L and delivers 60% of that value. An Automatic Correction Bolus will not occur within 60 minutes of a bolus that has been delivered or cancelled.
‡ Pricing current as of 3 November 2021 and subject to change without notice. Price per single pump update.
Tandem software updates are only available for in-warranty pumps. Upgrade linked to pump Serial Number and not transferable.
REFERENCES
1. Brown SA, Kovatchev BP, Raghinaru D, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Eng J Med. 2019;381(18):1701-1717.
2. Brown, S. Clinical acceptance of the artificial pancreas: Glycemia outcomes from a 6-month multicenter RCT. 2019 ADA 79th Scientific Sessions, San Francisco, CA.
RESPONSIBLE USE OF CONTROL-IQ TECHNOLOGY
Control-IQ™ technology does not prevent all high and low blood glucose events, and is not a substitute for meal boluses and active self-management of diabetes. Control-IQ technology will not be able to predict sensor glucose values and adjust insulin dosing if a patient’s CGM is not working properly or is unable to communicate with their pump. Patients should be instructed to always pay attention to their symptoms and blood glucose levels and treat accordingly.
IMPORTANT SAFETY INFORMATION
The t:slim X2 insulin pump and the t:slim X2 insulin pump with Control-IQ technology are intended for single patient use. The t:slim X2 pump and the t:slim X2 pump with Control-IQ technology are indicated for use with NovoRapid or Humalog U-100 insulin. t:slim X2 insulin pump: The t:slim X2 pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices. The t:slim X2 pump is indicated for use in individuals six years of age and greater. t:slim X2 insulin pump with Control-IQ technology: The t:slim X2 pump with Control-IQ technology is intended for use with a compatible continuous glucose monitor (CGM, sold separately) and the t:slim X2 pump to automatically increase, decrease, and suspend delivery of basal insulin based on CGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. The t:slim X2 pump with Control-IQ technology is intended for persons six years of age and greater.
WARNING: The t:slim X2 pump with Control-IQ technology should not be used by anyone under the age of six years old. It should also not be used in patients who require less than 10 units of insulin per day or who weigh less than 25 kilograms.
The t:slim X2 pump with Control-IQ technology is not indicated for use in pregnant women, people on dialysis, or critically ill patients. Do not use the t:slim X2 pump with Control-IQ technology if using hydroxyurea. Users of the t:slim X2 pump and the t:slim X2 pump with Control-IQ technology must: use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognise all functions of the pump, including alerts, alarms, and reminders. All Tandem Diabetes Care pumps, transmitters, and sensors must be removed before MRI, CT, or diathermy treatment. Visit tandemdiabetes.com/safetyinfo for additional important safety information.
New Zealand Medical and Scientific Limited: 2A Fisher Crescent, Mount Wellington, Auckland 1060